Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $198 | $197 | $201 | $203 |
| Gross Profit | -$198 | -$197 | -$201 | -$203 |
| % Margin | – | – | – | – |
| R&D Expenses | $13,370 | $24,511 | $26,327 | $26,559 |
| G&A Expenses | $5,734 | $6,605 | $7,808 | $8,094 |
| SG&A Expenses | $5,536 | $6,605 | $7,808 | $8,094 |
| Sales & Mktg Exp. | -$198 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,973 | $0 | $0 |
| Operating Expenses | $18,906 | $33,089 | $34,135 | $34,653 |
| Operating Income | -$19,104 | -$33,089 | -$34,135 | -$34,653 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,046 | $2,356 | $2,217 | $1,713 |
| Pre-Tax Income | -$17,058 | -$30,733 | -$31,918 | -$32,940 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,058 | -$30,733 | -$31,918 | -$31,227 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.65 | -0.68 | -0.69 |
| % Growth | 44.6% | 4.4% | 1.4% | – |
| EPS Diluted | -0.36 | -0.65 | -0.68 | -0.69 |
| Weighted Avg Shares Out | 47,124 | 47,095 | 46,656 | 45,410 |
| Weighted Avg Shares Out Dil | 47,124 | 47,095 | 46,656 | 45,410 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,241 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $198 | $197 | $201 | $203 |
| EBITDA | -$18,906 | -$32,892 | -$33,934 | -$34,450 |
| % Margin | – | – | – | – |